Can a common white blood cell booster shield the brain from Chemo-Radiation damage?

NCT ID NCT06649851

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 pilot study tests whether granulocyte colony stimulating factor (G-CSF), a drug that boosts white blood cells, can help preserve brain structure and thinking skills in people with a specific type of glioblastoma (MGMT-methylated) undergoing standard chemoradiation. About 60 newly diagnosed patients will receive either G-CSF plus standard treatment or standard treatment alone. The study measures brain volume changes on MRI and cognitive function over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Granulocyte colony stimulating factor (G-CSF, also called Filgrastim)
What this could lead to
If it works, this could point toward a way to reduce brain damage and cognitive decline from standard chemoradiation in glioblastoma patients.
What could go wrong
This is a small early-phase pilot study with only 60 participants, so results may not be conclusive. G-CSF may not provide meaningful brain protection, and side effects from the drug or chemoradiation remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.